Clinical trials in Vancouver, WA

29 recruiting studies have a site in or near Vancouver, WA, Washington.

Top conditions here

All conditions

Showing 29 of 29 studies

RecruitingPhase 3NCT06136650

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Sponsor: Merck Sharp & Dohme LLC

Spokane, WA · Vancouver, WA · +61 more sites

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Aberdeen, WA · Bellevue, WA · Bellingham, WA · +452 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Aberdeen, WA · Auburn, WA · Bellevue, WA · +1147 more sites

RecruitingPhase 3NCT06819878

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Hoffmann-La Roche

Seattle, WA · Vancouver, WA · +93 more sites

RecruitingPhase 3NCT07185009

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Sanofi

Vancouver, WA · +36 more sites

RecruitingPhase 2NCT07697456

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Sponsor: AbbVie

Bellevue, WA · Tacoma, WA · Vancouver, WA · +57 more sites

RecruitingPhase 3NCT06307665

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Sponsor: AstraZeneca

Bellingham, WA · Vancouver, WA · +118 more sites

RecruitingPhase 3NCT03678025

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Sponsor: SWOG Cancer Research Network

Bellevue, WA · Kirkland, WA · Seattle, WA · +331 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Vancouver, WA · +225 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Edmonds, WA · Kennewick, WA · Seattle, WA · +84 more sites

RecruitingPhase 2NCT07668388

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Sponsor: Novo Nordisk A/S

Vancouver, WA · +24 more sites

RecruitingPhase 2 / Phase 3NCT07155187

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Sponsor: AbbVie

Seattle, WA · Vancouver, WA · +14 more sites

RecruitingPhase not listedNCT05334069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Sponsor: Alliance for Clinical Trials in Oncology

Aberdeen, WA · Bellingham, WA · Burien, WA · +744 more sites

RecruitingPhase 1 / Phase 2NCT06362252

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Sponsor: Daiichi Sankyo

Vancouver, WA · +25 more sites

RecruitingPhase 3NCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Sponsor: AstraZeneca

Tacoma, WA · Vancouver, WA · Wenatchee, WA · +60 more sites

RecruitingPhase 3NCT07184931

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Sanofi

Bellevue, WA · Vancouver, WA · +123 more sites

RecruitingPhase 3NCT07184944

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Sanofi

Vancouver, WA · +33 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Seattle, WA · Vancouver, WA · +95 more sites

RecruitingPhase 3NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Sponsor: NRG Oncology

Aberdeen, WA · Bellevue, WA · Bellingham, WA · +1223 more sites

RecruitingPhase 3NCT07184996

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Sanofi

Bellevue, WA · Vancouver, WA · +116 more sites

RecruitingPhase 3NCT04423211

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Sponsor: ECOG-ACRIN Cancer Research Group

Aberdeen, WA · Bellingham, WA · Centralia, WA · +338 more sites

RecruitingPhase 3NCT05812807

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Sponsor: Alliance for Clinical Trials in Oncology

Bellevue, WA · Edmonds, WA · Issaquah, WA · +825 more sites

RecruitingPhase 3NCT06592924

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Sponsor: Canadian Cancer Trials Group

Aberdeen, WA · Bellevue, WA · Bellingham, WA · +371 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Aberdeen, WA · Auburn, WA · Bellevue, WA · +1226 more sites

RecruitingPhase 3NCT04852887

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Sponsor: NRG Oncology

Bellingham, WA · Edmonds, WA · Issaquah, WA · +809 more sites

RecruitingPhase not listedNCT07112924

CCM OPEN HF Registry

Sponsor: Impulse Dynamics

Vancouver, WA · +27 more sites

RecruitingPhase 2NCT05806515

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Sponsor: SWOG Cancer Research Network

Aberdeen, WA · Bellingham, WA · Bremerton, WA · +130 more sites

RecruitingPhase not listedNCT06073431

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

Sponsor: University of Rochester

Bellingham, WA · Longview, WA · Renton, WA · +222 more sites

RecruitingPhase 3NCT05929768

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Sponsor: SWOG Cancer Research Network

Aberdeen, WA · Bellevue, WA · Bellingham, WA · +952 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.